Endocan Corporation XCHC Excited to Announce Launch of New Website and Corporate Brand Endocan on Thursday, October 17, 2013 to Further Advance Industry-Driven Branding t
COLORADO SPRINGS, Colo., Oct. 14, 2013 /PRNewswire/ Endocan Corporation (NASDAQ OTC: XCHC) a U.S. Company specializing in cannabinoid formulation-based health and wellness solutions, is pleased to announce that the name change and the updated and revised Company website and corporate collateral package, will be released Thursday, October 17, 2013.
Endocan Corporation is creating an enhanced international brand and image with a blend of scientific expertise and patient orientated products to attack critical ailments and help promote an enhanced healthy autoimmune system to help maintain and regulate a strong healthy mind and body state with its proprietary cannabis based formulations and procedures.
Dr. Dorothy Bray, President & CEO, Endocan Corporation, stated, "We are on the cusp of our new product releases, designed for patients internationally. We will offer patients educational support and the opportunity of voluntary participation in our in-house tracking and anonymized data sharing systems through our new website noting patient feedback to improve future product development and new product release systems."
In the United States dispensary owners across the United States will be licensed to release the Company's brands and formulations for retail distribution through licensing agreements utilizing the Endocan brand name. In Canada the Company has an established network of professionals and regulatory experts to bring its products to market for patient use. Initially the Company will be releasing its formulations through several expert relationships across Canada. The Company has established two subsidiaries in The Netherlands, including Endocan B.V., for the Company's expanding European operations.
About Endocan Corporation
The brand name Endocan was chosen by the Board as a direct reference to the endocannabinoid system of the human body. The endocannabinoid system is a group of neuromodulatory compounds and their receptors that are involved in a variety of fundamental physiological processes including pain-sensation, immune function, stress, sleep, mood, appetite, and memory. Cannabinoids from plants, including those found in the Cannabis genus, as well as those autonomously produced within living biological systems, work together in the operation of the endocannabinoid system. The modulation of this system is the basis for cannabinoid-based medical treatments to assist patients to improve their health and well-being.
Endocan Corporation, (FKA The X-Change Corporation) is currently developing new natural cannabinoid containing products based on innovative formulations to utilize the unique and potent benefits of the cannabis and hemp plants. Medicinal properties of cannabis and hemp have been known and applied for thousands of years. With the aid of scientific research, Endocan Corporation is translating such knowledge into development of effective cannabinoid formulation-based health and wellness solutions as well as cosmeceutical, nutraceutical, and food brands throughout the world. The Company's health and wellness, nutritional, and cosmetics lines will address personal needs and will evolve with the introduction of new formulations and products, advancing the Company within the expanding multibillion-dollar global market.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. The Company does not undertake any duty nor does it intend to update the results of these forward-looking statements.
CFO, Sr Vp of Business Development
SOURCE Endocan Corporation